These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 3672429

  • 1. Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit.
    Cadroy Y, Caranobe C, Bernat A, Maffrand JP, Sié P, Boneu B.
    Thromb Haemost; 1987 Aug 04; 58(2):764-7. PubMed ID: 3672429
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S, Johansson K, Kjaer M, Elg M.
    Thromb Haemost; 2010 Dec 04; 104(6):1242-9. PubMed ID: 20806126
    [Abstract] [Full Text] [Related]

  • 3. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit.
    Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B.
    Thromb Haemost; 1992 Dec 07; 68(6):637-41. PubMed ID: 1287877
    [Abstract] [Full Text] [Related]

  • 4. The venous antithrombotic profile of naroparcil in the rabbit.
    Millet J, Theveniaux J, Brown NL.
    Thromb Haemost; 1994 Dec 07; 72(6):874-9. PubMed ID: 7740457
    [Abstract] [Full Text] [Related]

  • 5. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
    Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP.
    Thromb Haemost; 1997 Sep 07; 78(3):1142-9. PubMed ID: 9308768
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
    Jackson CV, Crowe VG, Frank JD, Wilson HC, Coffman WJ, Utterback BG, Jakubowski JA, Smith GF.
    J Pharmacol Exp Ther; 1992 May 07; 261(2):546-52. PubMed ID: 1578372
    [Abstract] [Full Text] [Related]

  • 7. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
    Roux S, Tschopp T, Baumgartner HR.
    J Pharmacol Exp Ther; 1996 Apr 07; 277(1):71-8. PubMed ID: 8613969
    [Abstract] [Full Text] [Related]

  • 8. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
    Bounameaux H, Ehringer H, Hulting J, Rasche H, Rapold HJ, Zultak M.
    Thromb Haemost; 1997 Sep 07; 78(3):997-1002. PubMed ID: 9308743
    [Abstract] [Full Text] [Related]

  • 9. Experimental studies on a recombinant hirudin, CGP 39393.
    Gray E, Watton J, Cesmeli S, Barrowcliffe TW, Thomas DP.
    Thromb Haemost; 1991 Apr 08; 65(4):355-9. PubMed ID: 2057916
    [Abstract] [Full Text] [Related]

  • 10. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
    Wong PC, Crain EJ, Watson CA, Zaspel AM, Wright MR, Lam PY, Pinto DJ, Wexler RR, Knabb RM.
    J Pharmacol Exp Ther; 2002 Dec 08; 303(3):993-1000. PubMed ID: 12438519
    [Abstract] [Full Text] [Related]

  • 11. Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor.
    Kaiser B, Markwardt F.
    Thromb Haemost; 1986 Apr 30; 55(2):194-6. PubMed ID: 3814237
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H.
    Thromb Haemost; 1997 May 30; 77(5):911-9. PubMed ID: 9184402
    [Abstract] [Full Text] [Related]

  • 13. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin.
    Diness V, Nielsen JI, Pedersen PC, Wolffbrandt KH, Ostergaard PB.
    Thromb Haemost; 1986 Jun 30; 55(3):410-4. PubMed ID: 3750271
    [Abstract] [Full Text] [Related]

  • 14. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
    Klootwijk P, Lenderink T, Meij S, Boersma H, Melkert R, Umans VA, Stibbe J, Müller EJ, Poortermans KJ, Deckers JW, Simoons ML.
    Eur Heart J; 1999 Aug 30; 20(15):1101-11. PubMed ID: 10413640
    [Abstract] [Full Text] [Related]

  • 15. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
    Berry CN, Girard D, Girardot C, Lochot S, Lunven C, Visconte C.
    Semin Thromb Hemost; 1996 Aug 30; 22(3):233-41. PubMed ID: 8836007
    [Abstract] [Full Text] [Related]

  • 16. [A study of human annexin V derivative: its effects of anticoagulation and antithrombosis].
    Ju CW, Wang LS, Yang X, Ma GS, Hua ZC, Gao XY.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Sep 30; 25(9):540-3. PubMed ID: 15569533
    [Abstract] [Full Text] [Related]

  • 17. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
    Kaiser B, Hauptmann J, Markwardt F.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Sep 30; 115(1-2):119-25. PubMed ID: 2459005
    [Abstract] [Full Text] [Related]

  • 18. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A.
    Eur Heart J; 2000 Sep 30; 21(17):1473-81. PubMed ID: 10952840
    [Abstract] [Full Text] [Related]

  • 19. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B, Fareed J.
    Thromb Haemost; 1996 Oct 30; 76(4):615-20. PubMed ID: 8903005
    [Abstract] [Full Text] [Related]

  • 20. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ, Gardell SJ, Holahan MA, Sitko GR, Stump GL, Wallace AA, Gilberto DB, Hare TR, Krueger JA, Dyer DL, Sanderson PE, Vacca JP, Shafer JA, Lynch JJ.
    J Pharmacol Exp Ther; 1999 Apr 30; 289(1):503-10. PubMed ID: 10087043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.